Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAWN: Daratumumab in NMOSD
NCT05403138Phase 3Active, not recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Nov 2022
- Primary completion
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of daratumumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Tianjin Medical University General Hospital. Started Nov 2022; status: active, not recruiting.
02
Drugs
daratumumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT05403138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05403138.